Correlation of prostate volume with severity of lower urinary tract symptoms as measured by international prostate symptoms score and maximum urine flow rate among patients with benign prostatic hyperplasia

Mudi Awaisu*, Muhammed Ahmed, Ahmad Tijjani Lawal, Abdullahi Sudi, Musliu Adetola Tolani, Nasir Oyelowo, Muhammad Salihu Muhammad, Ahmad Bello and Hussaini Yusuf Maitama

Abstract

Background: The aim of the study is to find the correlation between the prostate volume and severity of lower urinary tract symptoms (LUTS) as measured by international prostate symptoms score and maximum urine flow rate among patients with benign prostatic hyperplasia (BPH).

Methods: The study was a prospective correlational study conducted between June 2016 and November 2017. A total of 290 patients who presented with LUTS suggestive of BPH and satisfied the inclusion criteria were consecutively recruited. Clinical evaluation including digital rectal examination of the prostate was done. Symptoms severity was assessed using the self-administered international prostate symptoms score (IPSS) questionnaire. Prostate volume was determined by transrectal ultrasound scan, and the urine flow rate was measured using uroflowmeter. Data were analyzed using SPSS version 20.0, and p value < 0.05 was taken to be statistically significant.

Results: The mean age of the patients was 64.22 ± 9.04 years with a range of 40 to 95 years. Most of the patients had moderate symptoms (55%) on IPSS with the mean IPSS value of 16.41 ± 7.43. The mean Qmax value was 16.55 ± 7.41 ml/s, and the median prostate volume (IQR) was 45.05 (35, 59). There was a positive significant correlation between prostate volume and IPSS (r = 0.179, p = 0.002) and a negative significant correlation between prostate volume and Qmax (r = -0.176, p = 0.003).

Conclusion: This study showed a significant correlation between the prostate volume and IPSS, and also between prostate volume and maximum flow rate (Qmax).

Keywords: Benign prostatic hyperplasia, Prostate volume, International prostate symptoms score, Uroflowmetry

1 Background

Benign prostatic hyperplasia (BPH) refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone and clinically manifests as LUTS [1]. It is more common in men of African descent than Caucasians [2, 3]. The development of BPH and lower urinary tract symptoms (LUTS) is frequent events in aging males [4]. However, the relationship between BPH and LUTS is not a linear one, and some elderly patients with LUTS may not have BPH and vice versa. Clinically, BPH has been reported to occur in 8% of men at the age

*Correspondence: awaisudoc@yahoo.co.uk
Division of Urology, Department of Surgery, Ahmadu Bello University/ Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria
of 40 years rising to 50% and 90% by the ages of 60 and 80 years, respectively.

Most men who seek medical attention do so because of bothersome LUTS [5]. Many urologists use the symptoms as the basis for diagnosis of bladder outlet obstruction (BOO) and for assessment of treatment efficacy. The most widely used symptoms score is the International Prostate Symptom Score (IPSS). It is a reliable and valid instrument to measure subjective severity of lower urinary tract symptoms and progression over time.

Urodynamic investigation with pressure flow analysis is the preferred standard to measure the degree and site of obstruction; however, they are invasive and time-consuming [6]. To document obstruction, most urologists still use non-invasive objective parameters such as urinary flow rate, residual urine and prostate volume [7]. Prostate volume estimation is an important parameter in the management of patients with BPH. Prostate volume can be estimated by digital rectal examination (DRE); however, ultrasound, particularly transrectal ultrasound (TRUS), is more accurate and currently is considered as the gold standard. The use of transrectal ultrasound to objectively measure the prostate volume has been popularized since it was first introduced by Watanabe [8]. Prostate volume measurement is useful in aiding the choice of treatment modalities and calculating prostate-specific antigen density (PSAD) [2–4]. Several studies were done to correlate the prostate volume with the severity of lower urinary tract symptoms (LUTS), but the results were conflicting. While some of the studies showed significant correlation [9, 10], others did not demonstrate significant relationship [11]. Studies done on this subject from the available literature are sparse in the African population. Furthermore, some of the studies employed subjective measures only for the assessment of severity of LUTS. This study was conducted considering its strength in terms of larger sample size and utilizing both subjective (IPSS) and objective (uroflowmetry) parameters when compared with the previous ones done in Africa. Knowledge of the true relationship between LUTS and BPH will facilitate easy decision making in terms of diagnosis and treatment planning. The purpose of this study is to evaluate the relationship between the prostate volume and severity of LUTS as measured by IPSS and maximum flow rate (Qmax) among patients with benign prostatic hyperplasia.

2 Methods
A total of 290 patients with LUTS suggestive of BPH and aged 40 years and above were prospectively recruited from June 2016 to November 2017. Approval was obtained from the Health Research Ethics committee (HREC) of the hospital. Patients with suspected or histologically confirmed prostate cancer, patients already on medical therapy or had surgical intervention for BPH, patients with benign prostatic hyperplasia coexisting with urethral stricture and those with LUTS due to other causes were excluded from the study. Informed consent was obtained from all the patients. All enrolled patients were evaluated at the time of initial visit using the International Prostate Symptom Score (IPSS) which is a self-administered questionnaire. The questionnaire has seven items, and each has a score of 0 to 5 with total score of 35. It also assesses the quality of life which has values from 0 (delighted) to 6 (terrible). Patients were categorized into three groups as mild (0–7), moderate (8–19) and severe (20–35) symptoms. Because it is a self-administered questionnaire and not translated in the local language, many patients who did not understand the questions or who could not read English required assistance. Digital rectal examination (DRE) was done on each patient to assess the prostate size and characteristics. Patients with suspected malignant prostate were excluded from the study and investigated appropriately. All the participants had transrectal ultrasound (TRUS) to measure the volume of the prostate. TRUS was done using Mindray Digital Ultrasonic Diagnostic Imaging System: Model DP—20. The procedure was performed with the patients in the left lateral position using a well-lubricated gloved rectal probe at a frequency of 6.5 MHz. Prostate volume was calculated using the prolate ellipsoid formula (length × height × width × \(\pi/6\)) in cm\(^3\) (\(\pi/6\approx0.5238\)). Uroflowmetry was done using ARK Meditech System Uroflowmetry Machine: Urol 010 Model. All the patients voided while standing when they have strong urge to void. The maximum urine flow rate (Qmax) was obtained from the graph printed using EPSON LX-300-II Model printer.

3 Data analysis
The data obtained were recorded in a structured proforma and entered into statistical software. Analysis was subsequently done using Statistical Package for Social Sciences (SPSS) software version 20.0. Data were displayed in percentages, tables and charts, and the Pearson’s correlation coefficient (\(r\)) was used to describe the association between IPSS score, Qmax and prostate volume, while Chi-square was used for categorical variables. \(p\) value <0.05 was considered statistically significant.

4 Results
4.1 Socio-demographic parameters
A total of 290 patients met the inclusion criteria and were included in the study. The mean age of the patients was 64.22±9.04 years with a range of 40 to 95 years. The peak age group was 60–69 years as shown in Table 1.
Ninety-four patients (32.4%) were civil servants followed by 66 patients (22.8%) who were retired. Majority of the patients had moderate symptoms on IPSS as shown in Fig. 1. One hundred and forty-five patients (50%) had tertiary level of education. The symptoms severity based on the level of education is shown in Fig. 2.

The most common presenting LUTS was nocturia (97.2%), followed by frequency (89.0%), poor stream (82.4%), straining (79.7%), feeling of incomplete emptying (63.4%), urgency (51.7%), terminal dribbling (49.3%) and hesitancy (18.3%). Overall, the mean IPSS score was 16.41 ± 7.43. The quality of life (QoL) assessments showed that majority of the patients were unhappy with their symptoms (51.7%) as shown in Fig. 3.

The mean Qmax value was 16.55 ± 7.41 ml/s. The median prostate volume was 45.05 cm³ with IQR (35–59), and the mean prostate volume was 52.58 ± 30.53 cm³ (range 24.60–319.00 cm³). When the prostate volume and IPSS for the 290 patients were subjected to Pearson’s correlation coefficient test, there was a positive significant correlation ($r = 0.179$, $p = 0.002$). The correlation between prostate volume and Qmax showed a negative significant correlation ($r = -0.176$, $p = 0.003$), as shown in Table 2, and the scatter diagrams in Figs. 4 and 5.

### 5 Discussion

Benign prostatic hyperplasia and lower urinary tract symptoms are quite prevalent in men with advancing age [4]. Clinical BPH may not be life threatening; however, its manifestation as LUTS interferes with QoL [12]. In this study, the mean age of participants was 64.2 ± 9.0 years with a range of 40 to 95 years. This is similar to 64.4 ± 8.9 years found in the study done by Badmus et al. [13] in Ife, South-Western Nigeria. Other similar findings were seen in [7, 14, 15]. The peak age group was 60–69 years consistent with the studies done by Movsas et al. [3] and Udeh et al. [15]. This findings further support the fact that BPH is a disease of men with advancing age [4]. Majority of the patients in this study were civil servants 94 (32.4%) with tertiary level of education. This was in contrast with the finding by Udeh et al. [15] in which majority of patients (61.0%) were farmers. This

### Table 1 Age distribution of patients in the study population

| Age (years) | Frequency | Percent |
|-------------|-----------|---------|
| 40–49       | 19        | 6.6     |
| 50–59       | 46        | 15.9    |
| 60–69       | 138       | 47.6    |
| 70–79       | 75        | 25.9    |
| 80–89       | 10        | 3.4     |
| 90–99       | 2         | 0.7     |
| Total       | 290       | 100.0   |

Fig. 1 A pie chart showing the severity of symptoms based on IPSS
observation might be attributed to the fact that there are many higher institutions of learning in the study environment.

The mean IPSS value in this study was $16.3 \pm 7.1$ which was slightly different from the findings by Kenneth et al. [16] in Ghana and Ofoha et al. in Jos, Nigeria [17]. This difference may be due to a relatively larger sample size in
this study when compared with their own studies with sample size of 225 and 103 patients, respectively. Another reason could be due to delay in seeking treatment in our environment as majority of the patients present with moderate and severe LUTS.

The mean prostate volume was found to be similar to those obtained by Mohammed et al. [18] in Zaria, North-Western Nigeria, and Badmus et al. [13] in Ife, South-Western Nigeria. A different value was obtained by Gnyawali et al. [19] in Kathmandu, Nepal, though they use transabdominal ultrasound scan to calculate the prostate volume in their study.

The correlation of prostate volume with the International Prostate Symptoms Score (IPSS) was found to be significant in this study ($p=0.002$). Several studies were done to determine relationship between the prostate volume and severity of LUTS as measured by the IPSS, with various outcomes. A study done by Ofoha et al. [17] in Jos, North-Central Nigeria, reported a positive insignificant correlation between the prostate volume and IPSS. Similar findings of insignificant correlation between prostate volume and IPSS were also seen in other studies [7, 20, 21]. Some studies showed no relationship between prostate volume and IPSS [11, 22, 23], while some showed strong correlation [9, 10]. When the Qmax was correlated with the prostate volume, there was a negative significant correlation ($p=0.003$). This showed an inverse relationship between the prostate volume and the maximum flow rate, i.e., as the prostate volume increases, the maximum flow rate decreases.

The most common LUTS was found to be nocturia in 282 patients (97.2%) followed by frequency in 258 patients (89.0%) which was consistent with the finding by Oranusi et al. [24] Majority of the patients in this study described nocturia as the most bothersome LUTS affecting their QoL. Like other studies, the storage (irritative) symptoms were more frequent among the patients than the voiding (obstructive) symptoms [4].

Quality of life assessment showed that 150 patients (51.7%) and 42 patients (14.5%) were unhappy (QoL = 5) and mostly dissatisfied (QoL = 4), respectively. This demonstrated that lower urinary tract symptoms in patients with benign prostatic hyperplasia

| Test components         | Correlation (r-value) | p-value |
|-------------------------|-----------------------|---------|
| Prostate volume/IPSS    | 0.179                 | 0.002   |
| Prostate volume/Qmax    | -0.176                | 0.003   |

### Table 2 Correlation of prostate volume with IPSS and Qmax in the study population

IPSS International Prostate Symptoms Score, Qmax Maximum flow rate

*p*-value < 0.05 is statistically significant

---

![Fig. 4](image_url) Scatter diagram showing correlation between IPSS and prostate volume
significantly affect the quality of life. There was statistically significant relationship between the severity of LUTS assessed by IPSS and the QoL. This finding is consistent with the study by Patrick et al. [12] who concluded that it might be better to use the quality of life (QoL) as determinant of the choice of treatment, rather than the IPSS scores alone for prompt treatment of LUTS. Patients presented more with moderate IPSS symptoms (55.2%), mild symptoms (11.4%) and severe symptoms (33.4%), with the findings similar to that of Ofoha et al. [17]. Generally, our patients present late with moderate or severe LUTS probably because in many cases, mild symptoms are accepted as a natural occurrence with aging, and men learn to live with them. The level of education has no influence on presentation in this study, because majority still present with moderate and severe symptoms on IPSS despite having tertiary level of education. The limitation of the study includes problems with administration of International Prostate Symptoms Score questionnaire in those without formal education that require interpretation and or administration by the researcher, which may result in some level of bias in the ultimate IPSS score.

6 Conclusion
In conclusion, there was positive significant correlation between the prostate volume and International Prostate Symptoms Score (IPSS) and a negative significant correlation between prostate volume and maximum flow rate (Qmax). Therefore, in low resource settings where uroflowmetry is not readily available for the objective assessment of lower urinary tract symptoms, prostate volume could serve as a proxy parameter and complement subjective assessment with IPSS.

Abbreviations
BPH: benign prostatic hyperplasia; BOO: bladder outlet obstruction; LUTS: lower urinary tract symptoms; IPSS: international prostate symptoms score; QoL: quality of life; DRE: digital rectal examination; TRUS: transrectal ultrasound; Qmax: maximum flow rate; SPSS: statistical package for social sciences; IQR: inter-quartile range.

Acknowledgements
Not applicable.

Authors’ contributions
MA contributed to protocol development, data collection and manuscript writing. MAH contributed to data analysis, manuscript editing and manuscript revision. ATL contributed to data analysis, manuscript editing and manuscript revision. AS contributed to data collection, manuscript writing and manuscript revision. MAT contributed to data collection, data analysis and manuscript

Fig. 5 Scatter diagram showing correlation between Qmax and prostate volume
1. Lee C, Kozlowski J, Grayhack J (1997) Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 31:131–138
2. Hoke GP, Mc Williams G (2008) Epidemiology of benign prostatic hyperplasia in the community. Prostate 23:1–7
3. Movsas S (1966) Prostatic obstruction in the African and Asiatic. Br J Surg 53:538–543
4. Garraway WM, Collins GN, Lee RJ (1991) High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469–471
5. Tsang KK, Garraway WM (1993) Impact of benign prostatic hyperplasia on general well-being of men. Prostate 23:1–7
6. McGovern JD (1994) Why pressure-flow studies should be abandoned and not mandatory studies for evaluating men with benign prostatic hyperplasia. Urology 44:156–158
7. Ezz el Din K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Rosette JJ (1996) Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 48:393–397
8. Watanabe H, Kihara H, Tanaka M, Terasawa Y (1971) Diagnostic application of ultrasonotomography to the prostate. Invest Urol 8:548–559
9. Jian-ye W, Ming L, Yao-guang Z, Ping Z, Qiang D, Jian H et al (2008) Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia; a Chinese survey. Chin Med J 121:2042–2045
10. Cakiroglu B (2013) The correlation of symptoms severity and objective measures in patients with lower urinary tract symptoms. Clin Med Res 1:235–139
11. Agrawal CS, Chalise PR, Bhandari BB (2008) Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia. Nepal Med Coll J 10:104–107
12. Adeyemo PT, Adebayo PB, Aree PO. Severity of lower urinary tract symptoms among middle aged and elderly Nigerian men: impact on quality of life. Adv Urol. 2016. https://doi.org/10.1155/2016/1015796
13. Badmus TA, Asaleye CM, Badmus SA, Takue AO, Ibrahim MH, Arowolo OA (2012) Benign prostate hyperplasia: average volume in southwestern Nigerians and correlation with anthropometrics. Niger Postgrad Med J 19:15–18
14. Ojevolo RW, Ondota ES, Balogun OS, Alabi TO, Ajayi AI, Olajide TA et al (2017) Prevalence of clinical benign prostatic hyperplasia amongst community-dwelling men in a South-Western Nigerian rural setting: a cross-sectional study. Afr J Urol 23:109–115
15. Udoh EJ (2013) The relationship between prostate volume and international prostate symptom score in Africans with benign prostatic hyperplasia. Niger J Med 10:120–125
16. Kenneth A, Francis A, Christian GK, Ferguson LE, Emmanuel A, Benjamin TF et al (2016) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia among Ghanaian men: a hospital-based cross-sectional prospective study. Int J Res Med Sci 4:3905–3911
17. Ofoha CG, Shu’albi SJ, Akpayak IC, Dakum NK, Ramyil VM (2013) Relationship between prostate volume and ipss in African men with prostate disease. JOS J Med 9:16–19
18. Mohammed A, Bello A, Maitama HY, Ajibola HO, Lawal AT et al (2014) Determination of prostate volume and characteristics by transectal ultrasound among patients with lower urinary tract symptoms. Arch Int Surg 4:30–35
19. Grynavski D, Sharma U (2014) Correlation of prostate volume with ‘International Prostate Symptom Score’ and Benign Prostatic Hyperplasia-Impact Index’ in benign prostatic hyperplasia. JSM 17:1–5
20. Bosch JL, Hop WC, Kirkels WJ, Schroder FH (1995) The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age_prevalence and correlation of symptoms. Br J Urol 75:622–630
21. Sciarra A, D’Eramo G, Casale P, Loreto A, Buscanini M, Di Nicola S et al (1998) Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia. Prostate 34:121–128
22. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holmgren RL, Mebust WK et al (1992) The American Urological Association symptom index for BPH. J Urol 149:549–557
23. Ogwuwe NI, Dakum NK, Amu CO, Dung ED, Udhe E, Ramyil VM (2013) Problems with administration of International prostate symptom score in a developing community. Afr J Med 12:171–173
24. Oranusi CK, Nwofor AE, Mbonu O (2017) Correlation between International Prostate Symptom Score and Uroflowmetry in Patients with Benign Prostatic Hyperplasia. Niger J Clin Pract 20:454–458

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.